What Adbiotech does

Adbiotech Co., Ltd. (KOSDAQ: 179530) is a South Korean biotechnology company founded in June 2000 in Chuncheon, Gangwon-do, that develops and commercializes IgY (Immunoglobulin Yolk) antibodies derived from the egg yolks of immunized chickens, alongside a complementary VHH (nanobody) platform derived from camelid heavy-chain antibodies. The company's core proposition is producing high-titer antibodies at manufacturing costs reported as approximately 2,000 times lower than conventional IgG, enabling oral delivery as feed additives for livestock (cattle, swine, poultry) and aquaculture (shrimp, salmon, eel, yellowtail) as antibiotic and vaccine replacements, with selective extension into human health functional foods (Jayeonfore brand) and microbial products (BA-01 platform for food-waste disposers and mold inhibition). It holds 24 registered patents and 5 pending applications, with 25 trademarks including its IgY and VHH brand identities.

The company's go-to-market is primarily B2B, relying on direct sales to large farms and feed companies, an exclusive distribution partnership with Japan's Kyoritsu Pharmaceutical, a wholly-owned China sales subsidiary (AD Qingdao BIO-TECH), and additional distributor networks across approximately 10 countries including Vietnam, Thailand, Malaysia, Taiwan, Mongolia, and Bangladesh. Adbiotech lists more than five distinct revenue streams spanning animal health products, aquaculture pharmaceuticals, human functional foods, microbial/OEM solutions, and partnership royalties — most recently a 2026 co-development agreement with Nasdaq-listed Exicure combining Adbiotech's platform with Burixafor (GPC-100) in sickle cell disease, acute myeloid leukemia, and solid tumors. The company is publicly listed with 60 employees as of 2025 and FY2025 consolidated revenue of KRW 12,897 million; production facility utilization exceeded 100% in Q3 2021, prompting expansion of its Chuncheon manufacturing footprint.

Name

Adbiotech

Legal name

주식회사 애드바이오텍 (ADBIOTECH Co., Ltd.)

Website

https://adbiotech.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Animal health and aquaculture biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Other Animal Food Manufacturing (311119)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

akta.pro secondary industries

Antimicrobials & Anti-infectives (HLAMAEAE), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Medicated Feed Additives & Premixes (Veterinary Pharmaceuticals) (HLAMAEAN)

Keywords

• IgY antibody production
• Livestock health products
• Aquaculture disease prevention
• VHH nanobody therapeutics
• Health functional foods

Headquarters

HQ city

Chuncheon

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. IgY Animal Health Products: Sale of immunoglobulin yolk (IgY) antibody products for livestock (cattle, pigs, poultry) and aquaculture (shrimp, salmon, eel, yellowtail). Products include feed additives and veterinary pharmaceuticals replacing antibiotics and vaccines. Revenue generated from domestic Korean sales and exports to China, Japan, Vietnam, Thailand, Malaysia, Taiwan, Mongolia.
2. Aquaculture Products: Specialized aquatic animal health products including Ig-Guard product line for shrimp, salmon, eel, yellowtail. Aqua AD series antibiotics and feed additives for fish farming.
3. Health Functional Foods: Human health functional food products including Dr. QueenZ Balance (women's health), Dr. KingZ Balance (men's health), Gyngsta Slim (weight management), Sellingus Probiotics. Market expansion into functional food ingredients and individual certification products.
4. Microbial Products: Food waste disposer microbial products and mold inhibition solutions. Major home appliance company partnerships including LG Electronics for food waste disposer products.
5. Co-Development Royalties: Potential milestone payments and royalties from co-development agreement with Exicure for Burixafor (GPC-100) combination therapies in oncology and hematology indications.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Adbiotech produces and sells IgY (Immunoglobulin in Yolk) antibody-based feed additives and veterinary pharmaceuticals for livestock (cattle, pig, poultry) and aquaculture (shrimp, salmon, eel, yellowtail), marketed as antibiotic and vaccine alternatives. The company also sells human health functional foods (Jayeonfore brand) and microbial solutions for home appliances (LG partnership), supported by a VHH nanobody co-development program with Exicure. Core technology is egg-based antibody production from immunized chickens covering approximately 300+ pathogen antigens.

Differentiator

Problem solved

Functional benefit

Brands

• 다살린 (Dasalin): Livestock functional supplementary feed brand under the IgY product line
• 팜피온 (Farmpion)
• 자연포레 (자연포레 / Jayeonfore)
• Ig-Drink / Ig-Top
• Ig-Guard
• 아이지드링크 (IG-Drink)
• Aqua AD-Gluta / Aqua AD-Ne o / Aqua AD-Oxyneo / Aqua AD-Flor

Products and services

• Ig-Guard (Salmon) Feed supplement for salmon aquaculture that prevents and treats SRS disease by replacing antibiotics; efficacy validated at Santiago University field trials for export to Chilean salmon farms.
• Ig-Guard AY (Yellowtail) Feed supplement that prevents and treats Streptococcus and Nocardia diseases in farmed yellowtail, used as an antibiotic replacement; exclusively exported to Japanese antibiotic-free aquaculture farms.
• Ig-Guard AE (Eel) Feed supplement that prevents and treats Edwardsiella disease in farmed eel as an antibiotic replacement; exclusively exported to Japanese antibiotic-free aquaculture farms.
• Ig-Guard A (Shrimp) Feed supplement boosting immunity and productivity in farmed shrimp, preventing and treating AHPND (EMS), WSSV, and WFD diseases as an antibiotic alternative; efficacy verified in university experiments and field trials across China, Thailand, and Vietnam.
• IG-Drink / Ig-Top (Calf oral antibody products) Patented oral solution containing IgY immune protein for newborn calves and goats, marketed for rotavirus diarrhea prevention and immune enhancement; flagship IgY livestock product line sold under the IG-Drink brand.
• M10 (Hailbut) natural anti-parasitic Natural anti-parasitic agent for cultured flatfish developed jointly with Korea Research Institute of Bioscience and Biotechnology; controls scuticociliate parasites and provides immunity enhancement with no residual toxicity.
• Aqua AD-Gluta / Aqua AD-Neo / Aqua AD-Oxyneo / Aqua AD-Flor Aquaculture pharmaceutical product lines for treating bacterial diseases (Vibrio, Streptococcus, Edwardsiella) in fish and shrimp including eel, silverfish, trout, carp, yellowtail, and red sea bream.
• Jayeonfore (자연포레) health functional food brand Health functional food brand offering IgY-based supplements (Dr. QueenZ Balance for menopausal women, Dr. KingZ Balance for men, Gyngsta Slim for weight management, Sellingus Probiotics for gut health) sold through Korean B2C retail and digital channels.
• Burixafor (GPC-100) combination therapy program Co-developed combination therapy assets using Exicure's Burixafor compound combined with Adbiotech's antibody platform targeting sickle cell disease, acute myeloid leukemia, and solid tumor indications for clinical-stage development.

Quantifiable outcome

• 80%+ reduction in mortality rate in nanobody-treated calves vs control group
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, minor and strategic.

• Exicure, Inc.coreStrategic or Co-development Partner · 22 April 2026Co-development agreement for Burixafor (GPC-100) combination therapies targeting sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech conducts in vivo studies and preclinical validation; Exicure provides Burixafor compound and leads clinical/regulatory strategy. Programs may advance to IND-enabling studies and clinical trials.
• OQPBIOM Inc.minorOthers · 10 June 2025Target of acquisition by OQPBIOM. Quest PharmaTech opposes the acquisition as largest shareholder in OQPBIOM, evaluating legal options.
• LG ElectronicsstrategicChannel Partner/ Reseller/ Distributor · 18 February 2025Food waste disposer microbial product partnership with major Korean home appliance manufacturer. 2Q 2025 product launch planned. Also targeting large rental companies as customers for microbial products.
• JinselbiotechstrategicTechnology or Integration · 16 June 2023Plant cell culture technology partnership for large-scale nanobody antibody production. Leverages Jinselbiotech's recombinant protein production platform combined with Adbiotech's antibody development capabilities.
• WijuminorOthers · 8 February 2023Strategic share acquisition of Wiju for business diversification and synergy effects.wiju operates Noljang CONNECT, a traditional market online platform service connecting agricultural product producers directly with merchants.
• InnobackminorChannel Partner/ Reseller/ Distributor · 21 November 2022Overseas licensing agreement for next-generation swine vaccine products. Adbiotech obtained overseas supply rights for Mycoplasma and Circovirus vaccines from Innoback, expanding animal pharmaceutical pipeline.
• FrontBiostrategicTechnology or Integration · 6 September 2022Animal antiviral technology transfer agreement for expanding consumable disease prevention/treatment product pipeline. Focus on swine consumable disease therapeutics.
• Kangwon National UniversitystrategicStrategic or Co-development Partner · 16 July 2021Industry-academia research center establishment for local microorganism industry development. Joint research on industrial starter culture development and microorganism resource development. Development of BA-01 feed additive for Salmonella control in poultry.
• ThinkCreativeminorGTM or Marketing Partner · 4 May 2021Marketing partnership with health functional food and pharmaceutical marketing company. Digital IMC advertising agency partnership for health functional food marketing and distribution network expansion.
• Korea Biotechnology Research InstitutestrategicStrategic or Co-development Partner · 4 August 2020Technology transfer for Jeokchongchu (Hovenia dulcis) extract containing functional food ingredients. Transfer of 6 domestic and international patents for joint development of health functional food materials targeting joint health, atopy, and fibrosis. Human clinical trials underway at university hospitals.
• Kyoritsu Pharmaceutical (共立製藥)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Japan's largest animal pharmaceutical company (#1 in Japan, #11 globally). Exclusive distribution agreement for livestock, aquaculture, and pet IgY products in Japan since 2018. Strategic investment of approximately 1.2 billion KRW in 2019. Joint R&D and global market expansion collaboration.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Elanco Animal Health: Major global animal health company with a livestock portfolio spanning antibiotics, vaccines, and feed additives. Comparable as a broad incumbent in the same animal health customer base, with greater scale but lower specialization in antibody-based alternatives.
• Phibro Animal Health: Diversified animal health and nutrition company with livestock pharmaceutical and feed additive products. Comparable as a broad incumbent in the same livestock health and nutrition category where Adbiotech competes.
• Zoetis: Largest global animal health company offering vaccines, parasiticides, and diagnostics across livestock and companion animals. Overlaps with Adbiotech's livestock therapeutics franchise as a broad incumbent with established distribution channels and regulatory expertise.
• Virbac: Independent global animal health company with strong aquaculture and livestock pharmaceutical offerings, particularly in Asia. Comparable as a broad incumbent with overlapping aquaculture health products similar to Adbiotech's Ig-Guard line.

Direct peers

• Argenx: Belgium-based clinical-stage biotech pioneering VHH/nanobody therapeutics (efgartigimod). Closest technology peer to Adbiotech's VHH nanobody platform, demonstrating the commercial potential of camelid-derived single-domain antibodies in human therapeutics.
• EW Nutrition: Germany-based animal nutrition company with a significant IgY antibody product line (Globigen) targeting livestock gut health and disease prevention — directly comparable as IgY-based antibiotic-alternative feed additives serving the same livestock customer base.
• Ablynx (Sanofi): Original pioneer of VHH/nanobody technology acquired by Sanofi for ~$4.8B. The Ablynx platform pioneered camelid-derived single-domain antibodies — the same technological foundation as Adbiotech's VHH franchise, making it the canonical nanobody comparable.

Regional players

• Lee's Pharmaceutical: Hong Kong-listed pharmaceutical company with veterinary and animal health products across Asia. Comparable as a regional animal health peer in the same Asian distribution geography where Adbiotech's Kyoritsu and China subsidiary operate.

Emerging players

• CAMPRO Scientific (nanobody reagents): Provider of camelid VHH/nanobody reagents and services for research and diagnostics. Comparable as a niche player in the same VHH/nanobody technology space, though focused on research reagents rather than therapeutics.
• Imunova (IgY Nutrition): US-based IgY antibody company focused on human and animal health applications including immune support. Comparable as a niche IgY peer operating in a similar product category, though smaller and earlier-stage than Adbiotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adbiotech